BioRegenx, Inc.
BRGX
$0.01
-$0.0039-28.06%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.02M | 2.31M | 2.34M | 2.56M | 2.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.02M | 2.31M | 2.34M | 2.56M | 2.76M |
| Cost of Revenue | 454.80K | 625.50K | 681.80K | 844.00K | 952.90K |
| Gross Profit | 1.56M | 1.68M | 1.66M | 1.71M | 1.80M |
| SG&A Expenses | 3.17M | 4.22M | 7.09M | 5.81M | 8.60M |
| Depreciation & Amortization | 1.12M | 1.12M | 1.12M | 562.10K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.75M | 5.97M | 8.89M | 7.22M | 9.56M |
| Operating Income | -2.73M | -3.66M | -6.55M | -4.66M | -6.80M |
| Income Before Tax | -19.24M | -20.17M | -23.05M | -4.91M | -7.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.24 | -20.17 | -23.05 | -4.91 | -7.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.24M | -20.17M | -23.05M | -4.91M | -7.03M |
| EBIT | -2.73M | -3.66M | -6.55M | -4.66M | -6.80M |
| EBITDA | -1.53M | -1.93M | -4.33M | -3.01M | -5.73M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 3.84B | 3.84B | 3.65B | 3.38B | 3.04B |
| Average Diluted Shares Outstanding | 3.84B | 3.84B | 3.65B | 3.38B | 3.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |